Singapore Pharmaceuticals & Healthcare Report Q4 2014
Headline Expenditure Projections
- Pharmaceuticals : SGD990mn (USD790mn) in 2013 to SGD1.04bn (USD830mn) in 2014; +5.5% in local currency terms and +5.0% in US dollar terms. Forecast unchanged from Q 3 14.
- Healthcare: SGD17.78bn (USD14.21bn) in 2013 to SGD19.33bn (USD15.38bn) in 2014; +8.7% in local currency terms and +8.3% in US dollar terms. Forecast slightly downgraded from Q314.
Singapore's Pharmaceutical Risk/Reward Rating (RRR) score for Q414 is 62.1 out of the maximum 100 under our newly improved RRR system. The country scored above average for the majority of indicators and sub-indicators, including sector value growth, pensionable population and overall economic and political landscape. Consequently, with this high score, Singapore is ranked just slightly below other developed countries like Japan, Australia and South Korea, behind the highly attractive emerging Chinese market, and also behind Taiwan and Hong Kong.
Key Trends And Developments
The Singapore Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
- In June 2014 the Singaporean government stated that it supports the MediShield Life Review Committee's proposals to increase claim limits and lower co-insurance, particularly for the largest medical bills. As per the recommendations made by the review committee, Singaporean citizens will have to pay an additional 30% in premiums to the proposed MediShield Life universal healthcare insurance scheme for 10 years. The committee also suggested moves such as the removal of the lifetime claim limit of SGD300,000 (USD239,000) and for the government to cover most of the...
BMI's Singapore Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Singaporean pharmaceutical and healthcare industry.
- Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Singapore to test other views - a key input for successful budgeting and strategic business planning in the Singaporean pharmaceutical and healthcare market.
- Target business opportunities and risks in the Singaporean pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Singapore.
- Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.
BMI Industry View & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.
Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.
Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.
BMI Industry Forecasts
Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)
Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)
Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)
Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)
OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)
Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)
Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.
While Singapore's small population will limit the pharmaceutical market's overall growth potential, the government's commitment to healthcare as well as the ageing population will boost consumption of pharmaceuticals over the long term. In addition, the impending launch of the Association of South East Asian Nations Community in 2015 will increase Singapore's attractiveness to foreign pharmaceutical firms.
BMI Industry View
Pharmaceutical Market Forecast
Table: Pharmaceutical Sales, Historical Data And Forecasts (Singapore 2010-2018)
Healthcare Market Forecast
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Singapore 2010-2018)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Singapore 2010-2018)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Singapore 2010-2018)
Prescription Drug Market Forecast
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Singapore 2010-2018)
Patented Drug Market Forecast
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Singapore 2010-2018)
Generic Drug Market Forecast
Table: Generics Drug Market Indicators, Historical Data And Forecasts (Singapore 2010-2018)
OTC Medicine Market Forecast
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Singapore 2010-2018)
Pharmaceutical Trade Forecast
Table: Pharmaceutical Trade Data And Forecasts (Singapore 2012-2018)
Table: Pharmaceutical Trade Data And Forecasts local currency (Singapore 2012-2018)
Other Healthcare Data
Key Risks To BMI's Forecast Scenario
Global Liquidity Conditions Present Risks To Singapore-
-But State Of Economy Remains Sound
Table: Singapore - Economic Activity
Industry Risk Reward Ratings
Asia Risk/Reward Ratings
Singapore Risk/Reward Ratings
Industry Trends And Developments
Table: Top Causes Of Death In Singapore, 2010-2012
Table: Health Funding Sources In Singapore (SGDmn)
Healthcare Company Developments
International Healthcare Collaboration
Research & Development
Research & Development Activity
Intellectual Property Issues
Pricing And Reimbursement Regime
Table: Pharmaceutical Manufacturing In Singapore, 2004-2012
Table: Singapore's Leading Healthcare And Pharmaceutical Companies According To Market Capitalisation (USDmn)
Domestic Pharmaceutical Sector
Table: Multinational Pharmaceutical Firms' Presence In Singapore
Traditional Chinese Medicine
Pharmaceutical Retail Sector
Merck & Co
Table: Singapore's Population By Age Group, 1990-2020 ('000)
Table: Singapore's Population By Age Group, 1990-2020 (% of total)
Table: Singapore's Key Population Ratios, 1990-2020
Table: Singapore's Rural And Urban Population, 1990-2020
Pharmaceutical Expenditure Forecast Model
Healthcare Expenditure Forecast Model
Notes On Methodology
Risk/Reward Ratings Methodology
Table: Pharmaceutical Risk/Reward Ratings Indicators
This report does not have a list of Companies Mentioned available
This report does not have a press release associated with it